Telomir Pharmaceuticals (TELO) stock rocketed higher on Friday after the preclinical-stage biotechnology company posted data for Telomir-1. This is a potential cancer treatment in development that is currently in the preclinical stage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The big news today is Telomir-1’s ability to reverse epigenetic gene silencing in aggressive human prostate cancer cells. This revelation comes from a study of these cells in mice. Telomir Pharmaceuticals noted that Telomir-1 outperformed Paclitaxel and Rapamycin, two cancer treatments, in this study.
Telomir Pharmaceuticals CEO Erez Aminov said, “This study provides novel and direct molecular evidence of Telomir-1’s ability to reprogram cancer epigenetics. By potentially restoring the function of key tumor suppressor genes like STAT1, we’re not just slowing tumor growth-we’re turning the immune system back on.”
Telomir Pharmaceuticals Stock Movement Today
Telomir Pharmaceuticals stock was up 152.07% on Friday, extending a 5.22% rally from yesterday. Even so, the shares have fallen 70.63% year to date and 67.73% over the past 12 months. Today’s rally came with heavy trading, as some 57 million shares changed hands, compared to a three-month daily average of about 381,000 units.
